Incyte Pins Hopes On Phase III Jakafi Analysis In COVID-19 ARDS
Phase III Overall Negative, But Successful On Subset And Post-Hoc Analyses
Drugs for ARDS in COVID-19 have yielded mixed results in the clinic, with Boehringer Ingelheim pulling one from Phase II development earlier this month.
You may also be interested in...
Phase III results show benefit in cytokine-release syndrome, while other drugs for treating patients hospitalized with COVID-19 have produced mixed results.
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.
The Phase III failure of ruxolotinib contrasts with encouraging results and emergency use authorization for Lilly’s JAK inhibitor baricitinib in combination therapy.